Analysis of the relationship between lung cancer drug response level and atom connectivity dynamics based on trimmed Delaunay triangulation

Abstract Epidermal growth factor receptor (EGFR) mutation is a pathogenic factor of non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs), such as gefitinib, are widely used in NSCLC treatment. In this work, we investigated the relationship between the number of EGFR residues connected with gefitinib and the response level for each EGFR mutation type. Three-dimensional trimmed Delaunay triangulation was applied to construct connections between EGFR residues and gefitinib atoms. Through molecular dynamics (MD) simulations, we discovered that when the number of EGFR residues connected with gefitinib increases, the response level of the corresponding EGFR mutation tends to descend.

[1]  Barry Honig,et al.  Extending the accuracy limits of prediction for side-chain conformations. , 2001 .

[2]  Cinque S. Soto,et al.  Evaluating conformational free energies: The colony energy and its application to the problem of loop prediction , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Olivier Devillers,et al.  Complexity of Delaunay triangulation for points on lower-dimensional polyhedra , 2007, SODA '07.

[4]  Debby D Wang,et al.  The relationship between periodic dinucleotides and the nucleosomal DNA deformation revealed by normal mode analysis , 2011, Physical biology.

[5]  Valerie Daggett,et al.  Dynameomics: a consensus view of the protein unfolding/folding transition state ensemble across a diverse set of protein folds. , 2009, Biophysical journal.

[6]  Hong Yan,et al.  Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments , 2015, PloS one.

[7]  Hong Yan,et al.  Computational Evaluation of EGFR Dynamic Characteristics in Mutation-Induced Drug Resistance Prediction , 2015, 2015 IEEE International Conference on Systems, Man, and Cybernetics.

[8]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[9]  A. Onn,et al.  Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors. , 2012, Clinical lung cancer.

[10]  D. T. Lee,et al.  Two algorithms for constructing a Delaunay triangulation , 1980, International Journal of Computer & Information Sciences.

[11]  Antonino Fiannaca,et al.  Probabilistic topic modeling for the analysis and classification of genomic sequences , 2015, BMC Bioinformatics.

[12]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[13]  Hong Yan,et al.  Decoding the EGFR mutation-induced drug resistance in lung cancer treatment by local surface geometric properties , 2015, Comput. Biol. Medicine.

[14]  Mariette Yvinec,et al.  Triangulations in CGAL (extended abstract) , 2000, SCG '00.

[15]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[16]  Hong Yan,et al.  Personalized prediction of EGFR mutation-induced drug resistance in lung cancer , 2013, Scientific Reports.

[17]  E. Winer,et al.  Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Herbert Edelsbrunner,et al.  Three-dimensional alpha shapes , 1994, ACM Trans. Graph..

[19]  William C Hahn,et al.  Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants , 2005, PLoS medicine.

[20]  Hong Yan,et al.  Transcriptional Protein-Protein Cooperativity in POU/HMG/DNA Complexes Revealed by Normal Mode Analysis , 2013, Comput. Math. Methods Medicine.

[21]  Jing Liu,et al.  Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  Roy S Herbst,et al.  Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Hong Yan,et al.  EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib , 2015, BMC Bioinformatics.

[24]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[25]  G. Tortora,et al.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.